摘要
目的观察肺表面活性剂用于预防早产儿呼吸窘迫综合征(RDS)的临床效果。方法按照治疗方式的不同,将28例胎龄≤35周的早产儿作为观察组,出生后立即给予PS预防治疗,选取同期确诊为RDS的36例早产患儿为对照组,应用呼吸机与PS,对比两组患儿的RDS发生率与死亡率。结果观察组出现2例(7.1%)RDS,该院同期收治的胎龄≤35周的早产儿的RDS发生率为38.5%,两者相比差异有统计学意义(P<0.05)。对照组的RDS死亡率为8.3%,明显低于同期收治早产患儿RDS的死亡率28.5%,差异有统计学意义(P<0.05)。结论肺表面活性物质用于预防早产儿RDS时可以明显降低其发生率,效果显著,用于治疗早产儿RDS时可以显著降低死亡率,值得临床推广。
Objective To observe the pulmonary surfactant used to prevent premature respiratory distress syndrome （RDS）clinical effectl Methods According to the different methods of treatment, 28 cases of gestational age acuities 35 weeks premature as observation group, immediately after birth to the prevention and treatment of PS, select the diagnosed with RDS 36 cases of premature children as control group, the application of breathing machine and PS, compared to two groups of children RDS incidence and mortality. Results Observation group appear in 2 cases （7.1%） RDS, from our data were quartile gestational age 35 weeks premature RDS of rate of 38.5%, compared to the significant difference （P 〈 0.05）. Control group of RDS mortality was 8.3%, significantly lower than the same period of the children were RDS premature mortality rate 43.6%, the difference was significant （P 〈 0.05）. Conclusion Pulmonary surfactant used to prevent premature RDS can obviously decrease the hair.
出处
《中国卫生产业》
2013年第3期12-13,共2页
China Health Industry
关键词
肺表面活性物质
早产儿
呼吸窘迫
Pulmonary surfactant
Premature
Respiratory distress
